ArticleTranslational stroke research2026
Remote Ischemic Postconditioning Attenuates Neuroinflammation and Suggests a Potential Benefit for Early Neurological Recovery after Subarachnoid Hemorrhage via the IL-9/JAK2-STAT5 Signaling Pathway.
Article in Translational stroke research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Subarachnoid hemorrhage (SAH) often leads to cognitive impairment, in which neuroinflammation plays a pivotal role. While remote ischemic postconditioning (RIPostC) has demonstrated neuroprotective potential, its clinical efficacy and underlying mechanisms remain incompletely defined. This study identified interleukin-9 (IL-9) as a key mediator of RIPostC's effects through an integrated clinical and basic research approach. In a prospective proof-of-concept clinical trial, RIPostC was associated with improved early neurological recovery and significantly upregulated serum IL-9 levels in SAH patients. It suggests a potential clinical benefit that warrants further validation. Using a murine SAH model, results showed RIPostC improved cognitive function, suppressed pro-inflammatory cytokines (IL-1β, IL-6), and elevated anti-inflammatory cytokines (IL-9, IL-10). Mechanistically, RIPostC activated the JAK2/STAT5 signaling pathway. Immunofluorescence revealed specific expression of the IL-9 receptor (IL-9R) on microglia. In vitro experiments using BV2 microglial cells confirmed that IL-9 directly promotes microglial polarization towards an anti-inflammatory M2 phenotype and enhances IL-10 production via the JAK2/STAT5 pathway. Collectively, these preliminary findings suggest that RIPostC alleviates neuroinflammation and cognitive impairment after SAH, a process mechanistically linked to the upregulation of IL-9 and subsequent activation of the JAK2/STAT5 pathway in microglia. This study positions IL-9 as a promising therapeutic target for SAH.
Indexed as
Identifiers
42262450What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.